Search

A recent study conducted by researchers at the University of Chile focused on evaluating the replication kinetics of novel swine Influenza A viruses (IAVs) as a first step in vaccine production. The study used different swine IAV lineages, infection doses, harvest times, and substrates to gather data. The results showed that MDCK cells were the most efficient substrate for generating high titers of the virus. The researchers concluded that these findings could be valuable for vaccine-producing laboratories. This research has been peer-reviewed and published in the Austral Journal of Veterinary Sciences. [Extracted from the article]

A recent study conducted by researchers at the University of Bergen in Norway explored the impact of pre-existing immunity and age on antibody responses to the live attenuated influenza vaccine (LAIV). The study involved 31 children and 26 adults who were vaccinated with the trivalent LAIV during the 2013-2014 influenza season in Norway. The researchers found that LAIV elicited functional and neutralizing antibody responses in both naive and antigen-experienced individuals, but the magnitude and kinetics of the response varied between vaccine strains. The study highlights the importance of considering age and pre-existing immunity when assessing the effectiveness of LAIV. [Extracted from the article]

A recent study conducted at the University of Nebraska-Lincoln has developed a lipid nanoparticle-encapsulated DNA vaccine that shows promise in protecting against both swine and human-origin H1N1 influenza viruses. The vaccine was effective in inducing a robust immune response in pigs and mice, protecting them from infection with the respective viruses. This research is significant as swine influenza A virus is widespread and causes economic losses to the swine industry, and bidirectional transmission between swine and humans is common. The development of this vaccine could help mitigate the impact of the virus on the swine industry and prevent the emergence of reassortant strains. [Extracted from the article]

A recent study conducted at the University of Illinois Urbana-Champaign has found that natural variation in the activity of the neuraminidase (NA) enzyme can influence the evolutionary potential of the hemagglutinin (HA) protein in the seasonal H1N1 influenza A virus. The researchers observed substantial variation in the activity of NA proteins in a panel of H1N1 vaccine strains isolated between 2009 and 2019. They also found that the specific antibody escape profiles of HA were highly dependent on the NA background. These findings suggest that natural variation in NA activity plays a significant role in shaping the evolution of HA in the currently circulating H1N1 lineage. [Extracted from the article]

Researchers at Ohio State University have developed and characterized an intranasal vaccine platform using adjuvanted nanoparticulate delivery of swine influenza A virus (SwIAV). The vaccine, which employed whole inactivated H1N2 SwIAV as an antigen and STING-agonist ADU-S100 as an adjuvant, demonstrated high loading efficacy and non-cytotoxic properties suitable for intranasal vaccination. In a pig challenge trial, the intranasal vaccine induced cross-reactive sIgA antibodies in the respiratory tract and reduced viral replication in the nasal cavity. This novel vaccine platform shows potential effectiveness for pig immunization and represents a significant advancement in swine influenza vaccine design. [Extracted from the article]

A study conducted at King Saud University in Riyadh, Saudi Arabia, explored the association between H1N1 infection and the production of pro-inflammatory cytokines. The researchers investigated the cytokine profile of patients who underwent tonsillectomy and found a noticeable pro-inflammatory Th-1 and Th-17 response in H1N1-stimulated cells. The study highlights the importance of T-cells in mucosal immunity against H1N1 and suggests that intranasal vaccine candidates should trigger both cellular and humoral immune responses. This research provides valuable insights into the immune response to H1N1 infection and could contribute to the development of effective vaccines. [Extracted from the article]

A recent report from the Huzhou Center for Disease Control and Prevention in China provides new insights into the genetic characterization of the influenza A virus subtype H1N1. The study found that the virus has acquired mutations that can increase disease severity. However, the recommended vaccine strain A/Wisconsin/67/2022 is still effective against the circulating H1N1 virus in Huzhou. The virus in Huzhou currently has low pathogenicity and is naturally resistant to amantadines. Regular molecular surveillance is important to monitor changes in the virus and the emergence of new strains. [Extracted from the article]

A recent study from the University of Nebraska-Lincoln explores the challenges and potential strategies for developing a universal vaccine against Swine Influenza A Virus (IAV-S). The research highlights the significant impact of IAV-S on the pork industry and its potential threat to global public health. The study emphasizes the need for a broadly protective vaccine that can address the continuously evolving nature of IAV-S and overcome limitations of current vaccination strategies. The researchers also review novel vaccines and platforms that may improve IAV-S control. [Extracted from the article]

A recent study conducted at the University of Georgia has found that mRNA vaccines encoding computationally optimized hemagglutinin (HA) can elicit protective antibodies against future antigenically drifted H1N1 and H3N2 influenza viruses. Traditional seasonal influenza vaccines often provide limited protection against drifted viruses, but the use of mRNA vaccines has shown promise in generating robust neutralizing antibody responses. The study suggests that combining universal influenza antigen design technology with modern vaccine delivery platforms can lead to more effective vaccines against a broader range of influenza virus isolates. This research provides valuable insights into the potential applications of mRNA vaccines for infectious diseases beyond COVID-19. [Extracted from the article]

Researchers from the University of Palermo in Italy have conducted a study on the effectiveness of the influenza vaccine against the A(H1N1)pdm09 virus subtype during the 2023/24 flu season in Sicily. The study used virologic surveillance data and a test-negative design to estimate vaccine effectiveness. The results showed an overall adjusted vaccine effectiveness of 41.4%, with higher effectiveness observed among children aged 7 months to 14 years (37.9%) and the elderly (52.7%). The study also found higher vaccination rates among influenza-negative samples compared to positive samples in all age groups, except for individuals aged 45-64. [Extracted from the article]

A new report discusses research findings on the influenza A virus subtype H1N1. The study aimed to identify neuraminidase (NA) mutations in the influenza A/H1N1 and A/H3N2 subtypes in the Mazandaran province of Iran from 2016 to 2020. The researchers found no oseltamivir resistance-related mutations, but they did observe variations in the NA gene compared to vaccine strains. The study emphasizes the importance of constant monitoring for the emergence of drug resistance mutations. [Extracted from the article]

A recent study conducted by researchers at Cornell University explores the use of orf virus (ORFV) as a vector platform for delivering chimeric hemagglutinins (HA) of Influenza A virus of swine (IAV-S). The study aims to address the limitations of strain-specific immunity and antigenic diversity in IAV-S strains by redirecting immune responses to conserved epitopes of the stalk segment of the HA2 protein. The researchers generated two recombinant ORFVs expressing chimeric HAs and found that the resulting vaccine candidates induced cross-reactive immune responses and reduced viral shedding in vaccinated piglets. These findings suggest the potential use of chimeric HAs for preventing and controlling influenza in swine. [Extracted from the article]

A study conducted by researchers at Shanghai Jiao Tong University School of Medicine in China focuses on the construction of an mRNA vaccine for the hemagglutinin (HA) protein of the H1N1 influenza A virus. The researchers investigated different booster vaccination strategies and found that low-dose mRNA priming followed by both homologous mRNA vaccine and heterologous protein subunit vaccine booster vaccination induced stronger immune recall responses. The study highlights the potential of the M15-HA mRNA-LNP vaccine to generate immunogenicity and antibody neutralization activity. [Extracted from the article]

Two recent studies from the Centers for Disease Control and Prevention's VISION Network have found that flu vaccines were effective for all ages against both moderate and severe flu in the U.S. during the 2022-2023 flu season. Vaccination reduced the risk of flu-related emergency department visits and hospitalizations for both children and adults. The studies concluded that flu vaccination is likely to substantially reduce illness, death, and strain on healthcare resources. The effectiveness of the flu vaccine varied by age group, with greater risk reduction observed in younger children. The studies analyzed electronic health record data from healthcare systems in California, Utah, Minnesota, and Wisconsin. [Extracted from the article]

Zoetis, an animal health company, has filed a trademark application for "FLUSURE" for swine influenza vaccines. The application was made by Jane Ungaro and made available to the public on February 1, 2024. The trademark application is classified under goods and services code 005. This news article provides factual information about the trademark application and does not express any judgments or opinions. [Extracted from the article]

A new report from the Kenya Medical Research Institute-Wellcome Trust Research Program provides insights into the genetic and potential antigenic evolution of influenza A virus subtype H1N1 in Kenya from 2009 to 2018. The study analyzed genome sequences of the A(H1N1)pdm09 virus obtained from hospitalized patients and found multiple genetic groups of the virus circulating in Kenya. These groups evolved away from the vaccine strain, acquiring additional substitutions. The research emphasizes the importance of timely genomic surveillance to monitor the evolutionary changes of influenza viruses and highlights the need for routine influenza surveillance and whole genome sequencing to inform vaccine strain selection. [Extracted from the article]

A recent report from the National Center for Immunization and Respiratory Diseases discusses research findings on influenza A virus subtype H1N1. The study investigates how pre-existing antibodies can affect antibody responses to influenza vaccination in humans. The researchers found that pre-existing antibodies targeting a specific epitope on the virus can suppress antibody responses to the vaccine, but also induce the production of novel antibodies targeting other epitopes. This understanding is important for improving vaccine effectiveness. The full article can be accessed for free online. [Extracted from the article]

Keywords: Biological Products; Flu Vaccines; Health and Medicine; Immunization; Immunization and Public Health; Infectious Disease; Influenza; Influenza A Virus Subtype H1N1; Influenza A Virus Subtype H3N2; Influenza Vaccines; Orthomyxoviridae; RNA Viruses; Risk and Prevention; Swine Flu; Swine Influenza; Vaccination; Vaccines; Vertebrate Viruses; Viral Vaccines EN Biological Products Flu Vaccines Health and Medicine Immunization Immunization and Public Health Infectious Disease Influenza Influenza A Virus Subtype H1N1 Influenza A Virus Subtype H3N2 Influenza Vaccines Orthomyxoviridae RNA Viruses Risk and Prevention Swine Flu Swine Influenza Vaccination Vaccines Vertebrate Viruses Viral Vaccines 500 500 1 10/09/23 20231013 NES 231013 2023 OCT 10 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- A new study on influenza A virus subtype H3N2 is now available. Biological Products, Flu Vaccines, Health and Medicine, Immunization, Immunization and Public Health, Infectious Disease, Influenza, Influenza A Virus Subtype H1N1, Influenza A Virus Subtype H3N2, Influenza Vaccines, Orthomyxoviridae, RNA Viruses, Risk and Prevention, Swine Flu, Swine Influenza, Vaccination, Vaccines, Vertebrate Viruses, Viral Vaccines. [Extracted from the article]

The method of claim 2, wherein the influenza HA split vaccine is an influenza HA split vaccine of a single HA subtype. The method of claim 1, wherein the influenza HA split vaccine is an influenza HA split vaccine of a single HA subtype. The method of claim 3, wherein the influenza HA split vaccine is an influenza HA split vaccine of a single HA subtype. [Extracted from the article]

For more information on this research see: Use of Biolayer Interferometry to Identify Dominant Binding Epitopes of Influenza Hemagglutinin Protein of A(H1N1)pdm09 in the Antibody Response to 2010-2011 Influenza Seasonal Vaccine. Keywords: Antibodies; Antigens; Biological Products; Blood Proteins; Epitopes; Health and Medicine; Immunization; Immunoglobulins; Immunology; Infectious Disease; Influenza A Virus Subtype H1N1; National Center for Immunization and Respiratory Diseases; Orthomyxoviridae; Proteins; RNA Viruses; Swine Flu; Swine Influenza; U.S. Centers for Disease Control and Prevention; Vaccines; Vertebrate Viruses EN Antibodies Antigens Biological Products Blood Proteins Epitopes Health and Medicine Immunization Immunoglobulins Immunology Infectious Disease Influenza A Virus Subtype H1N1 National Center for Immunization and Respiratory Diseases Orthomyxoviridae Proteins RNA Viruses Swine Flu Swine Influenza U.S. Centers for Disease Control and Prevention Vaccines Vertebrate Viruses 1918 1918 1 09/11/23 20230911 NES 230911 2023 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Research findings on influenza A virus subtype H1N1 are discussed in a new report. [Extracted from the article]

The results of PCR-testing of 220,067 clinical samples revealed that the influenza A(H1N1)pdm09 virus dominated, causing 56.4% of positive cases, while A(H3N2) influenza subtype accounted for only 0.6%, and influenza B of Victoria lineage-for 34.3%. Keywords: Biological Products; Epidemic; Epidemiology; Flu Vaccines; Health and Medicine; Herd Immunity; Immunization; Immunization and Public Health; Infectious Disease; Influenza A Virus Subtype H1N1; Influenza B Virus; Influenza Vaccines; Orthomyxoviridae; Public Health; RNA Viruses; Risk and Prevention; Swine Flu; Swine Influenza; Vaccination; Vaccines; Vertebrate Viruses; Viral; Viral Vaccines; Virology EN Biological Products Epidemic Epidemiology Flu Vaccines Health and Medicine Herd Immunity Immunization Immunization and Public Health Infectious Disease Influenza A Virus Subtype H1N1 Influenza B Virus Influenza Vaccines Orthomyxoviridae Public Health RNA Viruses Risk and Prevention Swine Flu Swine Influenza Vaccination Vaccines Vertebrate Viruses Viral Viral Vaccines Virology 2050 2050 1 09/11/23 20230911 NES 230911 2023 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Investigators discuss new findings in influenza A virus subtype H1N1. [Extracted from the article]

Keywords: Antibodies; Biological Products; Blood Proteins; Enzymes and Coenzymes; Genetics; Glycoside Hydrolases; Health and Medicine; Immunization; Immunoglobulins; Immunology; Influenza; Influenza A Virus; Neuraminidase; Proteins; RNA Viruses; Risk and Prevention; University of Chicago; Vaccines; Viral; Virology; Viruses EN Antibodies Biological Products Blood Proteins Enzymes and Coenzymes Genetics Glycoside Hydrolases Health and Medicine Immunization Immunoglobulins Immunology Influenza Influenza A Virus Neuraminidase Proteins RNA Viruses Risk and Prevention University of Chicago Vaccines Viral Virology Viruses 3314 3314 1 08/07/23 20230811 NES 230811 2023 AUG 11 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- University of Chicago (Chicago, Illinois, United States) has been issued patent number 11702464, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. In some embodiments, provided herein are NA-reactive antibodies and antibody fragments that cross-bind to heterologous NA proteins (e.g., from human influenza, swine influenza, avian influenza, different NA types, etc.). In some embodiments, provided herein are epitopes to which the antibodies of the invention bind, and antibodies, antibody fragments, and/or modified antibodies based thereon (e.g., that bind to such epitopes). [Extracted from the article]

Biological Products, Clinical Research, Clinical Trials and Studies, Flu Vaccines, Health and Medicine, Immunization, Immunization and Public Health, Immunology, Infectious Disease, Influenza A Virus Subtype H1N1, Influenza Vaccines, Orthomyxoviridae, Public Health, RNA Viruses, Swine Flu, Swine Influenza, Vaccination, Vaccines, Vertebrate Viruses, Viral Vaccines Keywords: Biological Products; Clinical Research; Clinical Trials and Studies; Flu Vaccines; Health and Medicine; Immunization; Immunization and Public Health; Immunology; Infectious Disease; Influenza A Virus Subtype H1N1; Influenza Vaccines; Orthomyxoviridae; Public Health; RNA Viruses; Swine Flu; Swine Influenza; Vaccination; Vaccines; Vertebrate Viruses; Viral Vaccines EN Biological Products Clinical Research Clinical Trials and Studies Flu Vaccines Health and Medicine Immunization Immunization and Public Health Immunology Infectious Disease Influenza A Virus Subtype H1N1 Influenza Vaccines Orthomyxoviridae Public Health RNA Viruses Swine Flu Swine Influenza Vaccination Vaccines Vertebrate Viruses Viral Vaccines 1255 1255 1 07/17/23 20230721 NES 230721 2023 JUL 17 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- New research on influenza A virus subtype H1N1 is the subject of a new report. [Extracted from the article]

Keywords: Biological Products; Drugs and Therapies; Enzymes and Coenzymes; Health and Medicine; Immunization; Influenza A Virus; Orthomyxoviridae; Polymerase; RNA Viruses; Risk and Prevention; Swine Flu; Swine Influenza; Vaccines; Viral; Virology EN Biological Products Drugs and Therapies Enzymes and Coenzymes Health and Medicine Immunization Influenza A Virus Orthomyxoviridae Polymerase RNA Viruses Risk and Prevention Swine Flu Swine Influenza Vaccines Viral Virology 1954 1954 1 07/03/23 20230707 NES 230707 2023 JUL 7 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- Investigators discuss new findings in influenza A virus. For more information on this research see: Protein sequence features of H1N1 swine influenza A viruses detected on commercial swine farms in Serbia. [Extracted from the article]

Commonly used influenza vaccines at home and abroad at this stage include: whole virus inactivated vaccines, split vaccines, subunit vaccines, and live attenuated vaccines. Vaccines under development include: DNA vaccines, mRNA vaccines, recombinant vector vaccines, virus-like particle vaccines, general vaccines, etc. [Extracted from the article]

RNA Viruses - Influenza A Virus Subtype H1N1 Investigators publish new report on RNA Viruses - Influenza AVirus Subtype H1N1. Among 91 participants whoreceived egg-free influenza vaccines, 84 (92.3 %) received quadrivalentrecombinant influenza vaccine (RIV4, Flublok, Sanofi Pasteur), and 7(7.7 %) received quadrivalent cell culture-based influenza vaccine(ccIIV4, Flucelvax, Seqirus). [Extracted from the article]

Influenza A (H1N1) Monovalent Vaccine Influenza A (H1N1) 2009 Monovalent Influenza A (H1N1) 2009 Monovalent Vaccines Questions and Answers Monovalent Influenza Vaccine Dosage, Administration, and Storage (CDC) Influenza A (H1N1) 2009 Monovalent Vaccines Composition and Lot Release Influenza A (H1N1) 2009 Monovalent Vaccine Safety Monitoring Influenza A (H1N1) 2009 Monovalent Vaccine (CSL Limited) Influenza A (H1N1) 2009 Monovalent Vaccine (ID Biomedical Corporation of Quebec) Influenza A (H1N1) 2009 Monovalent Vaccine (MedImmune LLC) Influenza A (H1N1) 2009 Monovalent Vaccine (Novartis Vaccines and Diagnostics Limited) Influenza A (H1N1) 2009 Monovalent Vaccine (Sanofi Pasteur, Inc.) General Novel H1N1 Vaccination Recommendations Use of Influenza A (H1N1) 2009 Monovalent Influenza Vaccine in Pregnant Women Draft Guidance for Industry: Recommendations for the Assessment of Blood Donor Suitability, Blood Product Safety, and Preservation of the Blood Supply in Response to Pandemic (H1N1) 2009 Virus Fact Sheets Influenza (Flu) Antiviral Drugs and Related Information Keywords for this news article include: FDA, Biotechnology, Pharmaceutical Companies, Business, CSL Limited, Vaccination, Flu Vaccines, Bioengineering, Sanofi Pasteur, Viral Vaccines, Swine Influenza, Influenza Vaccines, Biological Products, Drugs and Therapies, Genetic Engineering, Health and Medicine, Immunization and Public Health. Bioengineering, Biological Products, Biologics, Biotechnology, Business, CSL Limited, Center for Biologics Evaluation and Research, Drugs and Therapies, FDA, Flu Vaccines, Genetic Engineering, Genetically-Engineered Proteins, Government Agencies Offices and Entities, Health and Medicine, Immunization, Immunization and Public Health, Influenza Vaccines, Pharmaceutical Companies, Public Health, Sanofi Pasteur, Swine Influenza, U.S. Food and Drug Administration, Vaccination, Vaccines, Viral Vaccines. [Extracted from the article]

Epidemiology, Health and Medicine, Influenza A Virus, Orthomyxoviridae, Pandemic, RNA Viruses, Risk and Prevention, Swine Flu, Viral, Virology, Swine Influenza Keywords: Epidemiology; Health and Medicine; Influenza A Virus; Orthomyxoviridae; Pandemic; RNA Viruses; Risk and Prevention; Swine Flu; Swine Influenza; Viral; Virology EN Epidemiology Health and Medicine Influenza A Virus Orthomyxoviridae Pandemic RNA Viruses Risk and Prevention Swine Flu Swine Influenza Viral Virology 2023 FEB 7 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- New research on influenza A virus is the subject of a new report. [Extracted from the article]